Indeed, MPs from SSc patients treated with methotrexate showed a reduced profibrotic potential, with Col1a1/MMP1 and Col1a2/MMP1 ratios close to those of HD (median of 0.49 vs. 0.68, respectively, Figure 4G and median of 0.72 vs. 0.98, respectively, Figure 4H), while they upregulated CCL2 expression, compared to the untreated patients and HD (median of 2.05 vs. 1.10 vs. 0.96, respectively, p<0.05 and p<0.005, Figure 4I). Here, CCL2 is linked to systemic sclerosis.